Showing posts with label trial results. Show all posts
Showing posts with label trial results. Show all posts
Friday, January 29, 2010
Thursday, January 28, 2010
Now's the time to find biomarkers on purpose -- Annals of Oncology
"Studies need to be conducted to determine the optimal design for using genome-wide profiling to identify putative biomarkers of drug response. To date, most biomarkers of drug response identified through genome-wide profiling have occurred through retrospective analysis of available tissue. To really progress this field, realistic planning for biomarker discovery and validation in clinical trials needs to be conducted. We, as clinical scientists, need to progress from only using convenient clinical cohorts to identify biomarkers to actually planning and following through with prospective clinical trials whose aims are to discover and/or validate putative biomarkers of drug response. To initiate a study without a realistic plan for discovery and validation reflects a lack of serious desire to find robust clinical predictors..... Until this becomes more commonplace, the genomic revolution will be focused on manuscript generation and investigator career development, leaving the benefit to patients nothing more than an unrealized dream."
add your opinions
biomarkers
,
cancer genetics risks
,
cancer.genetics
,
genome
,
incomplete
,
inheritance
,
interventions
,
lack of understanding
,
models
,
molecular
,
research
,
targeted
,
therapies
,
trial design
,
trial results
Friday, January 22, 2010
Analysis of Marshall Edwards, Inc.'s OVATURE Trial to Proceed Following Database Lock
"The OVATURE trial is a major multi-center international Phase III clinical trial of orally-administered investigational drug phenoxodiol in combination with carboplatin in women with advanced ovarian cancer resistant or refractory to platinum-based drugs, to determine its safety and effectiveness when used in combination with carboplatin.......The Company expects the final analysis will be performed strictly according to the protocol and now is expected to be completed in the second quarter of 2010"
add your opinions
Carboplatin
,
ovarian cancer
,
Ovature
,
phase 111
,
Phenoxodiol
,
platinum-resistant
,
refractory
,
trial results
Subscribe to:
Posts
(
Atom
)